The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
 
Danny Rischin
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Decibel Therapeutics (Inst); Erasca, Inc (Inst); Merck (Inst); Regeneron (Inst)
(OPTIONAL) Uncompensated Relationships - Eisai; GlaxoSmithKline; Merck; Regeneron
 
Sandro Porceddu
Leadership - Icon Cancer Care
Consulting or Advisory Role - Regeneron
Patents, Royalties, Other Intellectual Property - UpToDate
 
Fiona Day
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Varian Medical Systems
Travel, Accommodations, Expenses - Merck
 
Daniel Brungs
Honoraria - MSD
Consulting or Advisory Role - AstraZeneca/UK
 
Hayden Christie
Honoraria - Bayer
Travel, Accommodations, Expenses - MSD
 
James Jackson
Employment - Icon Cancer Center
Stock and Other Ownership Interests - Icon Cancer Center
 
Brian Stein
Stock and Other Ownership Interests - Holding Co pty Ltd
Consulting or Advisory Role - Bristol-Myers Squibb
 
Yungpo Su
No Relationships to Disclose
 
Gerard Adams
No Relationships to Disclose
 
Samantha Bowyer
Consulting or Advisory Role - Boehringer Ingelheim; Janssen; Medison; MSD; Roche
Speakers' Bureau - AstraZeneca/UK; Bristol-Myers Squibb/Medarex; MSD; Sanofi
Travel, Accommodations, Expenses - AstraZeneca/UK; Janssen Oncology
 
Zulfiquer Otty
Speakers' Bureau - AstraZeneca/UK; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca/UK; Bristol-Myers Squibb; MSD
 
Naoya Yamazaki
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Merck; Ono Pharmaceutical; Otsuka
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Novartis; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); HUYA Bioscience International (Inst); MSD (Inst); Novartis (Inst); Regeneron (Inst); Takara Bio (Inst)
 
Paolo Bossi
Honoraria - Angelini; BeiGene; Daiichi-Sankyo; Genmab/Seagen; GlaxoSmithKline; Merck; Merus; MSD Oncology; Pfizer; Regeneron; Sun Pharma
Consulting or Advisory Role - Angelini Pharma; Daiichi-Sankyo; Genmab/Seagen; GlaxoSmithKline; Merck Serono; MSD Oncology; Nutricia; Sanofi/Regeneron; Sun Pharma
Research Funding - BeiGene (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD Oncology (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Merck Serono
 
Amarnath Challapalli
Consulting or Advisory Role - Merck; Regeneron; Sanofi
Speakers' Bureau - Accord Healthcare; Bayer; Ipsen; Janssen; Merck; Regeneron
Research Funding - Regeneron
Travel, Accommodations, Expenses - Ipsen; Janssen
 
Rahul Ladwa
Honoraria - MSD (Inst); Sanofi (Inst)
Consulting or Advisory Role - La Roche-Posay (Inst); Merck Sharp & Dohme (Inst)
Research Funding - MSD
Travel, Accommodations, Expenses - MSD; Sanofi
 
Axel Hauschild
Honoraria - Agenus; Almirall Hermal GmbH; Bristol-Myers Squibb; CureVac; Immunocore; Incyte; IO Biotech; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Philogen; Pierre Fabre; Regeneron; Replimune; Roche; Sanofi/Aventis; Skyline Diagnostics; Sun Pharma; Xenthera
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Immunocore; IO Biotech; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Frank Seebach
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Suk-Young Yoo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Priscila Goncalves
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - I am an inventor on 2 patents, as a REGENERON employee - PCT publication 2023/133280 - PCT publication 2023/17772
 
Matthew Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneorn; Regeneron (I)